Summary

This book presents the development and initial clinical findings of acyclovir, a groundbreaking antiviral medication. Elion's central thesis is that rational drug design, based on understanding enzyme pathways essential to viral replication, can yield highly selective and effective antiviral agents. The book details the chemical synthesis of acyclovir and the scientific rationale behind its mechanism of action, targeting viral thymidine kinase and DNA polymerase to inhibit viral DNA synthesis. It also includes early data demonstrating acyclovir's efficacy against herpes simplex virus infections in humans.

Readers gain insight into the process of discovering and developing a specific antiviral drug, understanding the interplay between biochemistry, pharmacology, and clinical application. The work highlights the significance of targeting viral-specific enzymes, a strategy that proved foundational for future antiviral therapies. The book serves as a case study in medicinal chemistry and the preclinical and early clinical validation required for new drug introductions.

Full text isn't indexed yet — this overview draws on general knowledge of the book and its metadata, and chat works the same way.

Key concepts

Acyclovir — A synthetic guanosine analog that selectively inhibits herpesvirus replication by interfering with viral DNA synthesis.
Viral Thymidine Kinase — An enzyme produced by herpesviruses that phosphorylates acyclovir, initiating its activation.
Selective Toxicity — The principle of designing drugs that are toxic to the target (virus) but not to the host cells.
Antiviral Drug Development — The process of identifying, synthesizing, testing, and validating drugs to treat viral infections.